PI3K inhibitor/fulvestrant has modest benefit, serious toxicity in breast cancerJune 3, 2018Breast Cancer
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemoJune 3, 2018Breast Cancer
Should breast cancer screening guidelines be tailored to a patient’s race and ethnicity?May 31, 2018Breast Cancer
